ArticleNature biotechnology2015
Availability and payer coverage of BRCA1/2 tests and gene panels.
Article in Nature biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017Trial
- Patient and genetic counselor perceptions of in-person versus telephone genetic counseling for hereditary breast/ovarian cancer.Familial cancer · 2016Trial
- Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment.Journal of the National Comprehensive Cancer Network : JNCCN · 2023Article
- Outcomes of retesting in patients with previously uninformative cancer genetics evaluations.Familial cancer · 2022Article
- Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013-2018.Hereditary cancer in clinical practice · 2022Article
- A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries.Oncology and therapy · 2021Review
- Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study.JMIR research protocols · 2021Article
- Review
- The role of genomics in global cancer prevention.Nature reviews. Clinical oncology · 2021Review
- Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020Article
- The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace.The Journal of precision medicine · 2018Article
- From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2018Article
- Horizon Scan Of Clinical Laboratories Offering Pharmacogenetic Testing.Health affairs (Project Hope) · 2018Article
- Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.JMIR research protocols · 2017Article
- Payer coverage policies for multigene tests.Nature biotechnology · 2017Article
- Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.Journal of the National Comprehensive Cancer Network : JNCCN · 2017Article
- EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.International journal of technology assessment in health care · 2017Article
- Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.